GDMN
Price
$67.80Alerts
Change
-$4.65 (-6.42%)
Updated
Nov 12 closing price
Net Assets
153.51M
Intraday BUY SELL Signals
NEM
Price
$112.64Alerts
Change
-$5.83 (-4.92%)
Updated
Nov 12 closing price
Capitalization
127.4B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GDMN vs NEM

GDMN vs NEM Comparison Chart in %
View a ticker or compare two or three
VS
GDMN vs. NEM commentary
Nov 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GDMN is a Hold and NEM is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GDMN with price predictions
Nov 12, 2026

GDMN's Indicator enters downward trend

The Aroon Indicator for GDMN entered a downward trend on November 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 151 similar instances where the Aroon Indicator formed such a pattern. In 138 of the 151 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 58 cases where GDMN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GDMN as a result. In 65 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

GDMN moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GDMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

GDMN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GDMN's RSI Indicator exited the oversold zone, 22 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for GDMN just turned positive on November 04, 2026. Looking at past instances where GDMN's MACD turned positive, the stock continued to rise in 43 of 46 cases over the following month. The odds of a continued upward trend are 90%.

Following a +6.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where GDMN advanced for three days, in 308 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

A.I.Advisor
a Summary for NEM with price predictions
Nov 12, 2026

NEM in +4.55% Uptrend, growing for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NEM advanced for three days, in 249 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on NEM as a result. In 61 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for NEM just turned positive on November 04, 2026. Looking at past instances where NEM's MACD turned positive, the stock continued to rise in 40 of 57 cases over the following month. The odds of a continued upward trend are 70%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 61 cases where NEM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.

NEM moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.

NEM broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NEM entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 33 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 66, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 38 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.615) is normal, around the industry mean (2.121). P/E Ratio (15.190) is within average values for comparable stocks, (-12.498). Projected Growth (PEG Ratio) (2.781) is also within normal values, averaging (2.614). Dividend Yield (0.009) settles around the average of (0.330) among similar stocks. P/S Ratio (5.144) is also within normal values, averaging (7.321).

FUNDAMENTALS RATINGS
NEM: Fundamental Ratings
NEM
OUTLOOK RATING
1..100
29
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
33
SMR RATING
1..100
38
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
32
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GDMNNEM
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
64%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
65%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
69%
Advances
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
66%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
59%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
64%
View a ticker or compare two or three
Interact to see
Advertisement

GDMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GDMN has been closely correlated with WPM. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GDMN jumps, then WPM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GDMN
1D Price
Change %
GDMN100%
-6.42%
WPM - GDMN
93%
Closely correlated
-2.79%
AEM - GDMN
93%
Closely correlated
-4.06%
NEM - GDMN
91%
Closely correlated
-4.92%
KGC - GDMN
91%
Closely correlated
-3.54%
IAG - GDMN
90%
Closely correlated
-5.15%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GPAT11.06N/A
N/A
GP-Act III Acquisition Corp.
SNDX9.54-0.05
-0.52%
Syndax Pharmaceuticals
OLED89.89-0.65
-0.72%
Universal Display Corp
FISV61.50-2.40
-3.76%
Fiserv Inc.
BOLT5.91-0.35
-5.59%
Bolt Biotherapeutics Inc